Immunotherapeutic strategies in autoimmune uveitis

Autoimmunity Reviews

Volumn 13, Issue 9, 2014, Pages 909-916

  Papotto, Pedro Henrique ^a   Marengo, Eliana Blini ^a   Sardinha, Luiz Roberto ^a   Goldberg, Anna Carla ^a,b   Rizzo, Luiz Vicente ^a,b  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b Instituto de Investigação em Imunologia Instituto Nacional de Ciência e Tecnologia iii INCT   (Brazil)

Author keywords

Autoimmune uveitis; CD28 antagonists; Costimulation blockade; Experimental autoimmune uveitis; Immune modulation

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ANTIMETABOLITE; B7 ANTIGEN; CD28 ANTIGEN; CD3 ANTIBODY; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; ETANERCEPT; INDUCIBLE T CELL COSTIMULATOR; INFLIXIMAB; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MELANIN; MONOCLONAL ANTIBODY CD28; PROGRAMMED DEATH 1 RECEPTOR; TOSYLARGININE METHYL ESTER; ENDOTOXIN;

AUTOIMMUNE UVEITIS; CLINICAL TRIAL (TOPIC); DISEASE MODEL; ENDOTOXIN-INDUCED UVEITIS; EXPERIMENTAL AUTOIMMUNE UVEITIS; EXPERIMENTAL DISEASE; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; TRANSGENIC ORGANISM; ANIMAL; AUTOIMMUNE DISEASES; GRAFT VERSUS HOST REACTION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; UVEITIS;

ANIMALS; AUTOIMMUNE DISEASES; ENDOTOXINS; GRAFT VS HOST DISEASE; HUMANS; IMMUNE TOLERANCE; T-LYMPHOCYTES; UVEITIS;

EID: 84922613309     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.05.003     Document Type: Review

References (120)

1. Gritz D.C., Wong I.G. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004, 111(3):491-500. [discussion 500].
2. Whitcup S.M., Nussenblatt R.B. Immunologic mechanisms of uveitis. New targets for immunomodulation. Arch Ophthalmol 1997, 115(4):520-525.
3. Selmi C. Diagnosis and classification of autoimmune uveitis. Autoimmun Rev 2014, 13(4-5):591-594.
4. Comarmond C.B., Wechsler B., Bodaghi B., Cacoub P., Saadoun D. Biotherapies in Behcet's disease. Autoimmun Rev 2014, 13(7):762-769.
5. Selmi C., Gershwin M.E. Diagnosis and classification of reactive arthritis. Autoimmun Rev 2014, 13(4-5):546-549.
6. Jamilloux Y.L., Kodjikian L., Broussolle C., Seve P. Sarcoidosis and uveitis. Autoimmun Rev 2014, 13(8):840-849.
7. Sakata V.M., da Silva F.T., Hirata C.E., de Carvalho J.F., Yamamoto J.H. Diagnosis and classification of Vogt-Koyanagi-Harada disease. Autoimmun Rev 2014, 13(4-5):550-555.
8. Greco A., Fusconi M., Gallo A., Turchetta R., Marinelli C., Macri G.F., et al. Vogt-Koyanagi-Harada syndrome. Autoimmun Rev 2013, 12(11):1033-1038.
9. Wacker W.B., Donoso L.A., Kalsow C.M., Yankeelov J.A., Organisciak D.T. Experimental allergic uveitis. Isolation, characterization, and localization of a soluble uveitopathogenic antigen from bovine retina. J Immunol 1977, 119(6):1949-1958.
10. Gery I., Wiggert B., Redmond T.M., Kuwabara T., Crawford M.A., Vistica B.P., et al. Uveoretinitis and pinealitis induced by immunization with interphotoreceptor retinoid-binding protein. Invest Ophthalmol Vis Sci 1986, 27(8):1296-1300.
11. Roitt I.M. The role of autoantigens in the driving of autoimmune diseases. Immunol Ser 1993, 59:119-129.
12. Pennesi G., Mattapallil M.J., Sun S.H., Avichezer D., Silver P.B., Karabekian Z., et al. A humanized model of experimental autoimmune uveitis in HLA class II transgenic mice. J Clin Invest 2003, 111(8):1171-1180.
13. Medawar P.B. Immunological tolerance. Nature 1961, 189:14-17.
14. Caspi R.R. Ocular autoimmunity: the price of privilege?. Immunol Rev 2006, 213:23-35.
15. Ohta K., Wiggert B., Taylor A.W., Streilein J.W. Effects of experimental ocular inflammation on ocular immune privilege. Invest Ophthalmol Vis Sci 1999, 40(9):2010-2018.
16. Hamrah P., Dana M.R. Corneal antigen-presenting cells. Chem Immunol Allergy 2007, 92:58-70.
17. Forrester J.V., Xu H., Kuffova L., Dick A.D., McMenamin P.G. Dendritic cell physiology and function in the eye. Immunol Rev 2010, 234(1):282-304.
18. Griffith T.S., Ferguson T.A. The role of FasL-induced apoptosis in immune privilege. Immunol Today 1997, 18(5):240-244.
19. Usui Y., Okunuki Y., Hattori T., Kezuka T., Keino H., Ebihara N., et al. Functional expression of B7H1 on retinal pigment epithelial cells. Exp Eye Res 2008, 86(1):52-59.
20. Sugita S., Keino H., Futagami Y., Takase H., Mochizuki M., Stein-Streilein J., et al. B7+ iris pigment epithelial cells convert T cells into CTLA-4+, B7-expressing CD8+ regulatory T cells. Invest Ophthalmol Vis Sci 2006, 47(12):5376-5384.
21. Sugita S., Horie S., Nakamura O., Futagami Y., Takase H., Keino H., et al. Retinal pigment epithelium-derived CTLA-2alpha induces TGFbeta-producing T regulatory cells. J Immunol 2008, 181(11):7525-7536.
22. Zhou R., Caspi R.R. Ocular immune privilege. F1000 Biol Rep 2010, 2.
23. Forrester J.V., Xu H., Lambe T., Cornall R. Immune privilege or privileged immunity?. Mucosal Immunol 2008, 1(5):372-381.
24. Taylor A., Shang F., Obin M. Relationships between stress, protein damage, nutrition, and age-related eye diseases. Mol Aspects Med 1997, 18(5):305-414.
25. Yoshida M., Kezuka T., Streilein J.W. Participation of pigment epithelium of iris and ciliary body in ocular immune privilege. 2. Generation of TGF-beta-producing regulatory T cells. Invest Ophthalmol Vis Sci 2000, 41(12):3862-3870.
26. Zamiri P., Sugita S., Streilein J.W. Immunosuppressive properties of the pigmented epithelial cells and the subretinal space. Chem Immunol Allergy 2007, 92:86-93.
27. Sugita S., Horie S., Yamada Y., Keino H., Usui Y., Takeuchi M., et al. Suppression of bystander T helper 1 cells by iris pigment epithelium-inducing regulatory T cells via negative costimulatory signals. Invest Ophthalmol Vis Sci 2010, 51(5):2529-2536.
28. DeVoss J., Hou Y., Johannes K., Lu W., Liou G.I., Rinn J., et al. Spontaneous autoimmunity prevented by thymic expression of a single self-antigen. J Exp Med 2006, 203(12):2727-2735.
29. Biscette O.M.F., H.F., Flynn T.E. Uveitis Diagnosis. Management, and Treatment Retinal Physician 2007.
30. Rothova A., Buitenhuis H.J., Meenken C., Brinkman C.J., Linssen A., Alberts C., et al. Uveitis and systemic disease. Br J Ophthalmol 1992, 76(3):137-141.
31. Heo J., Sepah Y.J., Yohannan J., Renner M., Akhtar A., Gregory A., et al. The role of biologic agents in the management of non-infectious uveitis. Expert Opin Biol Ther 2012, 12(8):995-1008.
32. Smith J.A., Thompson D.J., Whitcup S.M., Suhler E., Clarke G., Smith S., et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005, 53(1):18-23.
33. Foster C.S., Tufail F., Waheed N.K., Chu D., Miserocchi E., Baltatzis S., et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003, 121(4):437-440.
34. Smith J.R., Levinson R.D., Holland G.N., Jabs D.A., Robinson M.R., Whitcup S.M., et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001, 45(3):252-257.
35. Caspi R.R. A look at autoimmunity and inflammation in the eye. J Clin Invest 2010, 120(9):3073-3083.
36. Gasparin F., Takahashi B.S., Scolari M.R., Gasparin F., Pedral L.S., Damico F.M. Experimental models of autoimmune inflammatory ocular diseases. Arq Bras Oftalmol 2012, 75(2):143-147.
37. Caspi R.R., Roberge F.G., Chan C.C., Wiggert B., Chader G.J., Rozenszajn L.A., et al. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol 1988, 140(5):1490-1495.
38. Wildner G., Kaufmann U. What causes relapses of autoimmune diseases? The etiological role of autoreactive T cells. Autoimmun Rev 2013, 12(11):1070-1075.
39. Sun B., Rizzo L.V., Sun S.H., Chan C.C., Wiggert B., Wilder R.L., et al. Genetic susceptibility to experimental autoimmune uveitis involves more than a predisposition to generate a T helper-1-like or a T helper-2-like response. J Immunol 1997, 159(2):1004-1011.
40. Rizzo L.V., Silver P., Wiggert B., Hakim F., Gazzinelli R.T., Chan C.C., et al. Establishment and characterization of a murine CD4+ T cell line and clone that induce experimental autoimmune uveoretinitis in B10.A mice. J Immunol 1996, 156(4):1654-1660.
41. Jones L.S., Rizzo L.V., Agarwal R.K., Tarrant T.K., Chan C.C., Wiggert B., et al. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J Immunol 1997, 158(12):5997-6005.
42. Tang J., Zhu W., Silver P.B., Su S.B., Chan C.C., Caspi R.R. Autoimmune uveitis elicited with antigen-pulsed dendritic cells has a distinct clinical signature and is driven by unique effector mechanisms: initial encounter with autoantigen defines disease phenotype. J Immunol 2007, 178(9):5578-5587.
43. Amadi-Obi A., Yu C.R., Liu X., Mahdi R.M., Clarke G.L., Nussenblatt R.B., et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007, 13(6):711-718.
44. Luger D., Silver P.B., Tang J., Cua D., Chen Z., Iwakura Y., et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 2008, 205(4):799-810.
45. Vallochi A.L., Commodaro A.G., Schwartzman J.P., Belfort R., Rizzo L.V., et al. The role of cytokines in the regulation of ocular autoimmune inflammation. Cytokine Growth Factor Rev 2007, 18(1-2):135-141.
46. Horai R., Silver P.B., Chen J., Agarwal R.K., Chong W.P., Jittayasothorn Y., et al. Breakdown of immune privilege and spontaneous autoimmunity in mice expressing a transgenic T cell receptor specific for a retinal autoantigen. J Autoimmun 2013, 44:21-33.
47. Chen J., Qian H., Horai R., Chan C.C., Falick Y., Caspi R.R. Comparative analysis of induced vs. spontaneous models of autoimmune uveitis targeting the interphotoreceptor retinoid binding protein. PLoS One 2013, 8(8):e72161.
48. Caspi R.R. Immunogenetic aspects of clinical and experimental uveitis. Reg Immunol 1992, 4(5):321-330.
49. Davey M.P., Rosenbaum J.T. The human leukocyte antigen complex and chronic ocular inflammatory disorders. Am J Ophthalmol 2000, 129(2):235-243.
50. Levinson R.D. Immunogenetics of ocular inflammatory disease. Tissue Antigens 2007, 69(2):105-112.
51. de Smet M.D., Yamamoto J.H., Mochizuki M., Gery I., Singh V.K., Shinohara T., et al. Cellular immune responses of patients with uveitis to retinal antigens and their fragments. Am J Ophthalmol 1990, 110(2):135-142.
52. Szpak Y., Vieville J.C., Tabary T., Naud M.C., Chopin M., Edelson C., et al. Spontaneous retinopathy in HLA-A29 transgenic mice. Proc Natl Acad Sci U S A 2001, 98(5):2572-2576.
53. Rosenbaum J.T., McDevitt H.O., Guss R.B., Egbert P.R. Endotoxin-induced uveitis in rats as a model for human disease. Nature 1980, 286(5773):611-613.
54. Broekhuyse R.M., Kuhlmann E.D., Winkens H.J. Experimental autoimmune anterior uveitis (EAAU). II. Dose-dependent induction and adoptive transfer using a melanin-bound antigen of the retinal pigment epithelium. Exp Eye Res 1992, 55(3):401-411.
55. Bora N.S., Kim M.C., Kabeer N.H., Simpson S.C., Tandhasetti M.T., Cirrito T.P., et al. Experimental autoimmune anterior uveitis. Induction with melanin-associated antigen from the iris and ciliary body. Invest Ophthalmol Vis Sci 1995, 36(6):1056-1066.
56. Matteson D.M., Shen D.F., Chan C.C. Inhibition of experimental melanin protein-induced uveitis (EMIU) by targeting nitric oxide via phosphatidylcholine-specific phospholipase C. J Autoimmun 1999, 13(2):197-204.
57. Rothlin C.V., Ghosh S., Zuniga E.I., Oldstone M.B., Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007, 131(6):1124-1136.
58. Lu Q., Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 2001, 293(5528):306-311.
59. Ye F., Li Q., Ke Y., Lu Q., Han L., Kaplan H.J., et al. TAM receptor knockout mice are susceptible to retinal autoimmune induction. Invest Ophthalmol Vis Sci 2011, 52(7):4239-4246.
60. Saadoun D., Bodaghi B., Bienvenu B., Wechsler B., Sene D., Trad S., et al. Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies. Autoimmun Rev 2013, 12(7):774-783.
61. Hoyer K.K., Dooms H., Barron L., Abbas A.K. Interleukin-2 in the development and control of inflammatory disease. Immunol Rev 2008, 226:19-28.
62. Banchereau J., Pascual V., O'Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol 2012, 13(10):925-931.
63. Chan C.C., Nussenblatt R.B., Wiggert B., Redmond T.M., Fujikawa L.S., Chader G.J., et al. Immunohistochemical analysis of experimental autoimmune uveoretinitis (EAU) induced by interphotoreceptor retinoid-binding protein (IRBP) in the rat. Immunol Invest 1987, 16(1):63-74.
64. Roberge F.G., Lorberboum-Galski H., Le Hoang P., de Smet M., Chan C.C., Fitzgerald D., et al. Selective immunosuppression of activated T cells with the chimeric toxin IL-2-PE40. Inhibition of experimental autoimmune uveoretinitis. J Immunol 1989, 143(11):3498-3502.
65. Higuchi M., Diamantstein T., Osawa H., Caspi R.R. Combined anti-interleukin-2 receptor and low-dose cyclosporine therapy in experimental autoimmune uveoretinitis. J Autoimmun 1991, 4(1):113-124.
66. Guex-Crosier Y., Raber J., Chan C.C., Kriete M.S., Benichou J., Pilson R.S., et al. Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol 1997, 158(1):452-458.
67. Nussenblatt R.B., Fortin E., Schiffman R., Rizzo L., Smith J., Van Veldhuisen P., et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A 1999, 96(13):7462-7466.
68. Nussenblatt R.B., Thompson D.J., Li Z., Chan C.C., Peterson J.S., Robinson R.R., et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 2003, 21(3):283-293.
69. Papaliodis G.N., Chu D., Foster C.S. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003, 110(4):786-789.
70. Yeh S., Wroblewski K., Buggage R., Li Z., Kurup S.K., Sen H.N., et al. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun 2008, 31(2):91-97.
71. Kung P., Goldstein G., Reinherz E.L., Schlossman S.F. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 1979, 206(4416):347-349.
72. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003, 3(2):123-132.
73. Ochi H., Abraham M., Ishikawa H., Frenkel D., Yang K., Basso A.S., et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25-LAP+ T cells. Nat Med 2006, 12(6):627-635.
74. Wu H.Y., Quintana F.J., Weiner H.L. Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+ CD25-LAP+ regulatory T cell and is associated with down-regulation of IL-17+ CD4+ ICOS+ CXCR5+ follicular helper T cells. J Immunol 2008, 181(9):6038-6050.
75. Herold K.C., Bluestone J.A., Montag A.G., Parihar A., Wiegner A., Gress R.E., et al. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992, 41(3):385-391.
76. Chatenoud L., Thervet E., Primo J., Bach J.F., et al. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 1994, 91(1):123-127.
77. Herold K.C., et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2years after onset of type 1 diabetes. Diabetes 2005, 54(6):1763-1769.
78. Utset T.O., et al. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol 2002, 29(9):1907-1913.
79. Ke Y., et al. Anti-CD3 antibody ameliorates experimental autoimmune uveitis by inducing both IL-10 and TGF-beta dependent regulatory T cells. Clin Immunol 2011, 138(3):311-320.
80. Dean Y., Depis F., Kosco-Vilbois M. Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases. Swiss Med Wkly 2012, 142:w13711.
81. Phillips B., Trucco M., Giannoukakis N. Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?. Clin Dev Immunol 2011, 2011:432016.
82. Gross J.A., Callas E., Allison J.P. Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol 1992, 149(2):380-388.
83. Greenwald R.J., et al. CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 2002, 32(2):366-373.
84. Yao S., et al. B7-h2 is a costimulatory ligand for CD28 in human. Immunity 2011, 34(5):729-740.
85. Greenfield E.A., Nguyen K.A., Kuchroo V.K. CD28/B7 costimulation: a review. Crit Rev Immunol 1998, 18(5):389-418.
86. Stebbings R., et al. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007, 179(5):3325-3331.
87. St Clair E.W. The calm after the cytokine storm: lessons from the TGN1412 trial. J Clin Invest 2008, 118(4):1344-1347.
88. Guinan E.C., et al. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994, 84(10):3261-3282.
89. Takahashi T., et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000, 192(2):303-310.
90. Stohl W., et al. Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity. J Immunol 2008, 181(1):833-841.
91. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12(4):252-264.
92. Ramsay A.G. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. Br J Haematol 2013, 162(3):313-325.
93. Romo-Tena J., Gomez-Martin D., Alcocer-Varela J. CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev 2013, 12(12):1171-1176.
94. Kremer J.M., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349(20):1907-1915.
95. Rosman Z., Shoenfeld Y., Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med 2013, 11:88.
96. Bluestone J.A., St Clair E.W., Turka L.A. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 2006, 24(3):233-238.
97. Salomon B., Bluestone J.A. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001, 19:225-252.
98. Moreland L.W., et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002, 46(6):1470-1479.
99. Larsen C.P., et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005, 5(3):443-453.
100. Tesavibul N., et al. Costimulatory molecules in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci 1998, 39(6):982-988.
101. Hardy K.M., et al. Benign mucous membrane pemphigoid. Arch Dermatol 1971, 104(5):467-475.
102. Fukai T., et al. The role of costimulatory molecules B7-1 and B7-2 in mice with experimental autoimmune uveoretinitis. Graefes Arch Clin Exp Ophthalmol 1999, 237(11):928-933.
103. Silver P.B., et al. Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J Immunol 2000, 165(9):5041-5047.
104. Verwaerde C., et al. Ocular transfer of retinal glial cells transduced ex vivo with adenovirus expressing viral IL-10 or CTLA4-Ig inhibits experimental autoimmune uveoretinitis. Gene Ther 2003, 10(23):1970-1981.
105. Zulian F., et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken) 2010, 62(6):821-825.
106. Kenawy N., et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 2011, 249(2):297-300.
107. Wu Y.L., et al. Immunotherapies: the blockade of inhibitory signals. Int J Biol Sci 2012, 8(10):1420-1430.
108. Lipson E.J., et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013, 19(2):462-468.
109. Ortler S., et al. B7-H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: implications for the lesion pathogenesis of multiple sclerosis. Eur J Immunol 2008, 38(6):1734-1744.
110. Reynolds J., et al. Stimulation of the PD-1/PDL-1 T-cell co-inhibitory pathway is effective in treatment of experimental autoimmune glomerulonephritis. Nephrol Dial Transplant 2012, 27(4):1343-1350.
111. Wong M., La Cava A., Hahn B.H. Blockade of programmed death-1 in young (New Zealand Black×New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease. J Immunol 2013, 190(11):5402-5410.
112. Sporici R.A., Perrin P.J. Costimulation of memory T-cells by ICOS: a potential therapeutic target for autoimmunity?. Clin Immunol 2001, 100(3):263-269.
113. Rottman J.B., et al. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat Immunol 2001, 2(7):605-611.
114. Hu Y.L., et al. B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells. J Immunol 2009, 182(3):1421-1428.
115. Usui Y., et al. The role of the ICOS/B7RP-1 T cell costimulatory pathway in murine experimental autoimmune uveoretinitis. Eur J Immunol 2006, 36(11):3071-3081.
116. Hunig T. Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv Immunol 2007, 95:111-148.
117. Poirier N., et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med 2010, 2(17):17ra10.
118. Poirier N., et al. Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody. Am J Transplant 2012, 12(10):2630-2640.
119. Poirier N., Blancho G., Vanhove B. A more selective costimulatory blockade of the CD28-B7 pathway. Transpl Int 2011, 24(1):2-11.
120. Poirier N., Blancho G., Vanhove B. CD28-specific immunomodulating antibodies: what can be learned from experimental models?. Am J Transplant 2012, 12(7):1682-1690.